6月3日 演題レポート
Abstract #LBA4001
Lapatinib in Combination with Capecitabine plus Oxaliplatin in HER2-positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: The TRIO-013/LOGiC Trial.
J. R. Hecht, et al.
Abstract #LBA4002
A Phase III Randomized Clinical Trial of Adjuvant Paclitaxel Followed by Oral Fluorinated Pyrimidines for Locally Advanced Gastric Cancer -SAMIT Study-
Kazuhiro Yoshida, et al.
Abstract #LBA4003
Comparison of Chemoradiotherapy (CRT) and Chemotherapy (CT) in Patients with a Locally Advanced Pancreatic Cancer (LAPC) Controlled after 4 Months of Gemcitabine with or without Erlotinib: Final Results of the International Phase III LAP 07 Study.
Hammel Pascal, et al.
Abstract #LBA4004
TeloVac: A Phase III Randomized Trial of Chemo-immunotherapy Comprising Gemcitabine and Capecitabine with or without Telomerase Vaccine GV1001 in Patients with Locally Advanced or Metastatic Pancreatic Cancer.
Gary W. Middleton, et al.
Abstract #4005
Results of a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel plus Gemcitabine versus Gemcitabine alone for Patients with Metastatic Adenocarcinoma of the Pancreas with PET and CA19-9 Correlates.
Daniel D. Von Hoff, et al.
Abstract #4008
JASPAC 01 : Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 for Patients with Resected Pancreatic Cancer.
Akira Fukutomi, et al.
Abstract #4019
Association of Gene Expressions of TOP2A, GGH, and PECAM1 with Hematogenous, Lymph-node, and Peritoneal Recurrence in Patients with Stage II/III Gastric Cancer Enrolled in the ACTS-GC Study.
Masanori Terashima, et al.
Abstract #4021
Clinical Outcome According to Tumor HER2 Status and EGFR Expression in Advanced Gastric Cancer Patients from the EXPAND Study.
Florian Lordick, et al.
Abstract #4023
COUGAR-02: A Randomized Phase III Study of Docetaxel versus Active Symptom Control in Patients with Relapsed Esophago-gastric Adenocarcinoma.
Natalie Cook, et al.
Abstract #LBA4024
Phase III Trial of a 3-weekly versus 5-weekly Schedule of S-1 plus Cisplatin (SP) Combination Chemotherapy for 1st-line Treatment of Advanced Gastric Cancer (AGC): SOS Study.
Min-Hee Ryu, et al.
Abstract #LBA10502
Randomized Phase III Trial of Imatinib (IM) Rechallenge vs. Placebo (PL) in Patients (pts) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) after Failure of at least both IM and Sunitinib (SU) : RIGHT Study.
Yoon-Koo Kang, et al.
Abstract #10503
Mutational Analysis of Plasma DNA from Patients in the Phase III GRID Study of Regorafenib vs. Placebo in Tyrosine Kinase Inhibitor-refractory GIST: Correlating Genotype with Clinical Outcomes.
George D. Demetri, et al.
